| |
Vivaldi Biosciences is a biotechnology company developing advanced vaccines for prevention of common seasonal influenza (“flu”) and emergent pandemic flu. The company is deploying world-class science leadership and patented technologies in the development and production of novel live attenuated influenza vaccines (LAIVs) with a unique mode of action. Vivaldi’s initial focus is development of a LAIV for seasonal flu that provides improved protection for adults age 50 and over. Older adults are among the most vulnerable to flu and its serious complications, but available vaccines generally are less effective or not approved for adults over age 49. In preclinical studies, Vivaldi’s LAIVs induce potent and protective antibody and cellular immune responses. Studies in animal models also indicate the vaccines’ potential to provide long-lasting immunity and cross-protection to mismatched influenza strains with a single low-dose immunization. Vivaldi’s proprietary technology is applicable to rapid development and production of LAIVs against virtually all seasonal and pandemic influenza strains, including novel (swine-origin) H1N1. The company is developing methods for rapid, scalable and cost-effective LAIV production with both standardized cell culture and traditional egg substrate methods. Vivaldi plans to file an Investigational New Drug application and begin clinical trials of its lead LAIV candidates in 2010.
|
|
|
